Beacon claimed the findings represent the first time a treatment for X-linked retinitis pigmentosa, a rare and potentially ...

At a “capital markets day” in London, executives outlined a roadmap to better compete with key rival Eli Lilly and soon bring forth several multibillion-dollar products.

Worth $1.65 billion up front, the deal combines two large pipelines and manufacturing networks, helping Telix potentially “corner the industry” for radiopharmaceuticals, one analyst wrote.

In an interview with BioPharma Dive, Compass executives said that, should the FDA approve their treatment, they hope to capitalize on a strategy pioneered by J&J in selling the ketamine spray Spravato ...

The occurrence of “neuropsychiatric” adverse events in testing fueled investor doubts about a drug the FDA is already reviewing for a form of epilepsy.

The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...

Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success ...

Nearly a dozen biotechnology firms have matched or raised more than $300 million in their initial public offerings in 2026, a figure not seen since new stock sales peaked in 2021, according to ...

Marea’s acquisition by Lisata, alongside a $225 million financing deal, will back development of a pair of medicines in mid-stage testing for cardiovascular and endocrine conditions.

The potentially $1.4 billion alliance will see the two companies collaborate on “macrocycles” that could yield oral ...

Armed with $180 million and a dual-acting antibody for eczema, the startup is capitalizing on a change in sentiment that’s led to a sudden spike in reverse merger deals.